Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983198 | 0.86 | CYP3A4 (0.44) | PPARAPPARGCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL27632520 | 0.84 | ALDH1A1 (0.68) | CYP3A4ALDH1A1SMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL28278094 | 0.84 | MMP8 (0.50) | PPARACYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL28278097 | 0.82 | LMNA (0.47) | PPARAPPARGCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL11681237 | 0.81 | KLK7 (0.44) | PPARAPPARGCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL15464042 | 0.81 | CYP3A4 (0.42) | PPARACYP3A4ALDH1A1SMN1; SMN2KLK7 | |
| SCHEMBL187655 | 0.81 | CYP3A4 (0.42) | PPARACYP3A4ALDH1A1SMN1; SMN2KLK7 | |
| SCHEMBL29094176 | 0.81 | KLK7 (0.44) | PPARAPPARGCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL1203770 | 0.81 | CRHBP (0.53) | CYP3A4ALDH1A1SMN1; SMN2CYP2D6CYP1A2 | |
| SCHEMBL6040370 | 0.81 | KMT2A (0.51) | PPARACYP3A4ALDH1A1KLK7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664428-B2 | Method for producing (2,4-dimethylbiphenyl-3-yl)acetic acids, the esters thereof and intermediate compounds | BAYER CROPSCIENCE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-4175185-A | ESTERIFICATION, IMINOHALOGENATION, ETHERIFICATION, HYDROLYSIS, DEESTERIFICATION | MEIJI SEIKA KAISHA LTD. (JP) | 1979-11-20 | — | — | US | disclosed |
| US-3998816-A | 7-[5-N-(n-Butoxyethoxy carbonyl and 2-chloroethoxy carbonyl)-amino] cephalosporins C | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | DDC, DDT, PAH | PPARA 650/4885PPARG 1206/4885CYP3A4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.